Adult Cancer Screening Schedule

Screening · §92

A small set of screening tests — done on schedule — prevents more cancer deaths per hour of patient effort than almost anything else in adult medicine. The current US Preventive Services Task Force schedule covers five cancers (breast, cervix, colon, lung, skin), and four of them have decades of large trials behind them; the fifth is widely practiced but unsettled. What follows is the schedule itself, what each test actually catches, and where the real decisions are — start ages, intervals, and which test to pick.

Do · Yearly Evidence Strong Chapter Screening

The longevity payoff is large per hour spent — this sits near the top of preventive medicine's leverage list. The schedule is free for almost every insured American and the effort is minor: a handful of appointments a year, with the colonoscopy prep day being the worst single piece. The catch worth knowing: false positives and overdiagnosis are real, and the right decisions on start age, which test to use, and whether to bother with skin exams are genuinely contested at the edges.

Screening works two ways depending on the cancer. For cervical and colon cancer, the test finds and removes precancerous tissue — abnormal cells on the cervix, polyps in the colon — so the cancer never forms. Cervical screening has cut cervical cancer incidence by 60–70% in screened populations Ronco 2014; the longest colonoscopy cohort study showed a 68% drop in colorectal cancer death among people who had one Nishihara 2013.

For breast and lung cancer, the test doesn't prevent the cancer — it finds it small, before it has spread, when surgery alone can usually cure it. The big lung trial that established CT screening (the NLST) showed a 20% drop in lung cancer deaths and a 6.7% drop in all deaths over about six years NLST 2011. Mammography catches breast cancers at lower stage and smaller size; the mortality reduction across the trials is roughly 15–30% Tabár 2011.

Skin sits in a third category. A clinician (or you) looks at the skin for lesions that look different from the rest — asymmetric, irregular border, multiple colors, growing. Whether routine visual exams in healthy adults actually save lives has not been settled by a randomized trial, and the USPSTF has held an insufficient-evidence position on it since 2009 USPSTF 2023.

The schedule

For average-risk adults with no family history or strong risk factors, the current USPSTF schedule:

Breast (women, 40–74). Mammogram every two years USPSTF 2024.
Cervix (women, 21–65). Ages 21–29: Pap smear every three years. Ages 30–65: choice of Pap every three years, OR high-risk HPV test every five years, OR both together every five years. Stop at 65 if recent screens have been clear USPSTF 2018.
Colon (everyone, 45–75). Pick one: an at-home stool test (FIT or stool DNA) every year, OR colonoscopy every ten years, OR flexible sigmoidoscopy every five years. The test you'll actually do on schedule is the right one USPSTF 2021.
Lung (current and former smokers, 50–80). Annual low-dose CT scan if you have a 20+ pack-year smoking history and currently smoke or quit within the last 15 years USPSTF 2021.
Skin. No graded schedule. The USPSTF says the evidence isn't there for routine full-body exams in healthy adults. High-risk people (prior melanoma, many unusual moles, organ transplant) see a dermatologist on a personalized schedule USPSTF 2023.

One pack-year is a pack a day for a year. Twenty pack-years is a pack a day for 20 years, or two packs a day for 10. Most current and former heavy smokers qualify; most don't know they do, and only about 6% of eligible Americans actually get the scan Wolf 2024.

None of this is the whole picture if you have a family history. A first-degree relative diagnosed with colon cancer at 45 shifts your colonoscopy start to 35. A BRCA1 or BRCA2 mutation puts breast screening on MRI plus mammogram in your late twenties. The risk-adjusted schedule lives further down the article.

Why this is the schedule

Cancer screening has more big-trial evidence behind it than almost any other preventive medicine. Each piece of the schedule above is built on data the rest of the catalogue rarely sees.

For breast cancer, eight randomized trials run from the 1960s to the 1990s plus a Swedish cohort followed for 29 years converge on a 15–30% reduction in breast cancer death in women invited to screen Marmot 2013 Tabár 2011. For colon cancer, the Minnesota stool-blood trial showed a 33% reduction in colon-cancer mortality with annual at-home testing over 13 years Mandel 1993.

For cervical cancer, four European randomized trials of HPV-based screening showed a 60–70% reduction in invasive cervical cancer compared to Pap-only screening Ronco 2014. US cervical cancer mortality has fallen from about 14 per 100,000 in the 1950s to 2.2 per 100,000 today — almost entirely because of Pap and HPV screening Siegel 2024.

Skin is the outlier. A German mass-screening project saw a 48% drop in melanoma deaths after one round, but it was an observational study and the effect didn't hold up at longer follow-up Katalinic 2012. The USPSTF concluded in 2023 — for the third time — that there's still not enough evidence to recommend routine skin exams in healthy adults USPSTF 2023.

How the schedule changes with risk

The default schedule assumes you're average risk. Several things move the start date earlier, the interval shorter, or both.

Family history of colon cancer. A first-degree relative (parent, sibling, child) diagnosed before 60 means colonoscopy starts 10 years before the relative's age at diagnosis — or at 40, whichever is earlier — and repeats every five years instead of ten Smith ACS 2020.
BRCA1 or BRCA2 mutation, or a strong family history of breast cancer. Annual MRI plus annual mammogram starting at 25–30. Risk-reducing surgery is a separate, bigger conversation.
Lynch syndrome. Colonoscopy every one to two years from age 20–25, lifelong. Plus screening for endometrial, gastric, and urinary cancers.
Dense breast tissue. The imaging center now has to tell you (most US states require it). Supplemental ultrasound or MRI is often offered through insurance; the USPSTF says the evidence for it isn't fully there yet, but most dense-breast patients get the extra scan anyway USPSTF 2024.
Heavy smoker who doesn't quite fit the USPSTF lung window. The American Cancer Society in 2023 dropped the 15-year quit-window requirement; some pulmonologists will screen you regardless Wolf 2024.
Many atypical moles, prior melanoma, organ transplant, or very fair skin with heavy sun history. Dermatology will set you up on a personalized full-body-exam interval — usually every six to twelve months — even though the USPSTF hasn't endorsed it for the general population.

Two notes on sex. Cervical screening applies to anyone with a cervix, including trans men who haven't had a hysterectomy. Mammography is for women; male breast cancer is rare enough that the USPSTF doesn't screen for it unless there's a BRCA mutation in the family. Trans women on long-term feminizing hormones don't have a USPSTF recommendation; specialty consensus is to start mammography after five or more years of hormone therapy, at age 50 or older.

Cost, time, and how it fits into a normal life

For insured Americans, the Affordable Care Act mandates zero cost-sharing on every USPSTF Grade A or B preventive service at the recommended interval — meaning the screening itself is free at the door. The follow-up workup after a positive screen (a diagnostic mammogram, a biopsy, a second colonoscopy after a positive stool test) sometimes hits a copay or deductible depending on the plan. Uninsured adults can use the CDC's free breast-and-cervical screening program for income-eligible women, plus state-level colon screening programs.

Time commitments per round, in normal-life units: a mammogram is 20 to 30 minutes plus travel; a Pap smear is 5 to 10 minutes tacked onto a routine visit; the at-home stool test is 5 minutes and a stamp; a colonoscopy is 90 minutes plus a day of clear-liquid prep and a half-day of recovery; a low-dose lung CT is 10 minutes plus the drive; a full-body skin exam is 10 minutes at a clinic. The annual aggregate, for an adult on the full average-risk schedule, is a couple of hours.

The week of any given screen carries a small but real emotional rhythm — a low background hum of dread beforehand, the relief of a clean result, or the cortisol spike of a callback. Being current on the schedule is also a quiet kind of agency: you're not waiting for symptoms to find out. Neither effect is large day to day; both are real, and worth knowing about going in.

What most people get wrong

"Earlier detection is always better." Sometimes; sometimes not. Some screen-detected cancers — mostly slow-growing breast tumors and small lung nodules — would never have caused symptoms or shortened life. The patient still gets surgery, radiation, sometimes chemotherapy. The current estimate is that 19–30% of mammography-detected breast cancers are overdiagnosed Welch 2016; NLST overdiagnosed about 18% of the lung cancers it caught Aberle 2013. Screening still saves more lives than it overtreats, but the overtreatment is real.
"More frequent is better." Mostly false. Annual mammograms roughly double the false-positive rate over a decade compared to every two years, without a clear mortality difference for average-risk women. Cervical screening every year — the old US default — gave way to every three to five years because the extra benefit was tiny and the colposcopy-and-biopsy harm wasn't USPSTF 2018.
"At-home stool tests are second-best." Annual at-home stool testing has comparable mortality benefit to colonoscopy in modeling studies Lew 2019. The harder problem isn't the test, it's doing it every year for thirty years. The right colon test is the one you'll actually do on schedule.
"A clean screen means I don't have cancer." It means the test didn't find one. Interval cancers — ones that grow fast enough to appear between screens — happen in every program. A new breast lump, blood in stool, blood in your cough, or a mole that's changing all get worked up regardless of when your last screen was.
"The annual full-body skin exam is well-evidenced." It isn't. The USPSTF has held an insufficient-evidence position on routine skin screening since 2009 and reaffirmed it in 2023 USPSTF 2023. Dermatologists routinely do them and many patients find them useful; the trial data hasn't caught up.
"All the cancer organizations agree." They don't. The American College of Radiology recommends annual mammography from 40; the American Cancer Society says annual from 45, then biennial from 55; the USPSTF since 2024 says biennial from 40 Monticciolo 2023 Oeffinger 2015. ACS in 2023 dropped the quit-window for lung CT; the USPSTF kept it Wolf 2024. The disagreements are at the edges, and they're real.

Where screening falls apart in practice

You don't do it on schedule. Single-round screening of any modality helps a little. The mortality benefit comes from sustained on-schedule participation over decades. National US numbers: about 70% up to date for breast, 75% for cervical, 70% for colon, and just 6% of eligible adults for lung Smith ACS 2020 Wolf 2024.
Nobody asks the family history question carefully. A first-degree relative with colon cancer at 45 shifts your start age from 45 to 35. A grandmother and an aunt with breast cancer shifts the genetic-testing conversation forward by a decade. Most primary care visits don't dig beyond a checkbox.
You qualify for lung screening and don't know it. Pack-year math is unfamiliar territory. A pack a day from 25 to 45 is twenty pack-years, and at 50 you qualify even if you quit five years ago. About 14 million Americans fit the criteria; the vast majority haven't been screened Wolf 2024.
The false-positive cascade. About 10% of mammograms get called back for additional imaging. Roughly 3% of lung CTs lead to biopsy. Colonoscopy has a complication rate around 2%, with serious bleeding or perforation around 0.05% USPSTF 2021. None of this is enough to make screening net-negative on average, but the harm path is real and worth knowing about going in.
You keep screening past the stopping age. Mammography in your 80s and colonoscopy after 75 usually aren't recommended for average-risk people — the lead time to mortality benefit is five to ten years, and a screen-detected cancer in someone with limited life expectancy mostly leads to treatment without a survival gain.

When to skip or stop

Life expectancy under ten years. The lead time from a screen-detected cancer to a mortality benefit is usually five to ten years. If you're frail, terminally ill, or in active treatment for another life-limiting condition, the screen detects cancers you won't live to be harmed by — but you still go through the diagnostic workup. The stopping ages baked into the schedule (65 for cervical, 75 for breast and colon, 80 for lung) are rough proxies for this; for individuals, the conversation is about life expectancy, not the calendar.
Pregnancy. Mammography is generally postponed except to evaluate a specific finding. Low-dose CT is not done unless symptoms drive it. Pap smears are fine; biopsy of high-grade dysplasia is usually deferred to after delivery.
Hysterectomy with the cervix removed for benign reasons, no high-grade history. Cervical screening stops permanently.
Procedure-specific issues. Severe bleeding disorders, a recent heart attack, or active abdominal infection make colonoscopy unsafe and push you toward stool-based testing.

What an unscreened decade actually looks like

Anchor on a 55-year-old. The base-rate lifetime cancer-death risks from these five sites, with no screening, run roughly: 2.5% for breast (women), 1.8% for colon, 6.5% for lung in heavy smokers (0.5% in never-smokers), 0.3% for melanoma, 0.2% for cervical (women) Siegel 2024. Small per year, large over a lifetime.

The felt version of those numbers: something like a 1 in 30 to 1 in 50 chance, across the next decade, of presenting with a symptomatic cancer that the schedule would have caught earlier. Symptomatic colon cancer is fatigue and weight loss and blood you notice in the toilet bowl — usually Stage II or III by the time someone images, treatable but with months of surgery and chemotherapy. Symptomatic lung cancer is a cough that doesn't clear up, with 5-year survival below 20% once it's Stage IV. Symptomatic breast cancer is a lump that someone — you, a partner, a GP at a physical — feels, almost always more than a centimeter across by then.

People around you start telling these stories in their late fifties and sixties. The colleague who put off the colonoscopy and got diagnosed at Stage III. The aunt whose lump was a year of dismissed back-pain before someone scanned her. The schedule is the version of you that doesn't end up in those stories — not certainly (interval cancers still happen) but at materially better odds.

What changes if you follow the schedule

Day to day, almost nothing. The aggregate effect over a lifetime is large but invisible — the polyp removed at colonoscopy at 50 was the colon cancer you didn't get at 62; the small abnormality found on mammogram at 53 was the chemotherapy you didn't need at 58. You can't perceive the alternate timeline you avoided.

Week of any given screen: an hour at the imaging center or 90 minutes at the GI lab, the brief uncertainty of waiting for the result, the relief or the callback. Year by year: one or two appointments. Decade by decade: an absolute reduction in lifetime cancer-death risk of roughly half a percentage point to one percentage point across the five sites — modest in absolute numbers, but among the highest-leverage moves in adult preventive medicine in life-years saved per hour spent Lin 2021.

The partner-noticing effect is mostly negative space: you keep being alive and asymptomatic into your seventies while the schedule does its job, and nobody around you registers what didn't happen. The visible payoff is the call from your gastroenterologist three days after the colonoscopy — "we found and removed two polyps, see you in five years" — five extra years of certainty for ninety minutes of inconvenience and a day of clear-liquid prep.

HPV vaccination prevents most cervical cancer cases upstream of any screening test — a Swedish cohort of 1.7 million women showed an 88% reduction in invasive cervical cancer in those vaccinated before age 17 Lei 2020. Prostate cancer screening (PSA testing) is a separate conversation with a USPSTF Grade C in men 55–69, meaning it's an individual shared-decision call rather than a default Johansson 2020. Genetic testing for BRCA1, BRCA2, Lynch syndrome, and other heritable cancer mutations is the upstream conversation that rewrites the schedule for the people who carry them. UV-protection behavior (sunscreen, hats, shade in the middle of the day) is the better-evidenced cousin of skin screening: the USPSTF gives behavioral counseling for fair-skinned people through age 24 a B grade Henrikson 2018. Multi-cancer early-detection blood tests — the single-blood-draw screens now marketed as a way to catch dozens of cancers at once — are the tempting new option, but none has yet matched the trial evidence behind the five screens here; treat them as a possible add-on, not a substitute, and get the proven ones done first.

Related in the handbook

Alternatives

— Before paying for a multi-cancer blood test, make sure the proven screens on this schedule are actually done — they save lives the blood test hasn't yet shown it does.

— The cancer screens drop neatly into a once-a-year cadence of preventive visits.
— Colorectal cancer is one of the cancers this schedule tells you when to screen for.
— For long-term smokers, add the annual lung scan to the standard cancer-screening line-up.
— PSA is the asterisk on the cancer-screening lineup: discuss it first, since the harms are real.
— Beyond the five cancers, the aortic-aneurysm ultrasound is another high-value age-based screen for older men.
— Vaccines and cancer screens are the two pillars of grown-up prevention — and HPV shots prevent cancer outright.
— Several cancers on this schedule are alcohol-driven; cutting back lowers the risk these tests are hunting for.
— Breast screening is one of the cancers on the combined schedule.
— Cervical cancer is one of the cancers this schedule tells you when to screen for.
— The HPV catch-up shot prevents several of the cancers this schedule screens for, so it's worth doing alongside the checks.
— Skin cancer is the DIY entry on the cancer-screening list: five minutes a month at the mirror.

Substance and claimed effects

Adult cancer screening is the systematic application of tests in asymptomatic adults to detect cancer (or its high-grade precursors) before symptoms appear, with the aim of reducing cancer-specific and all-cause mortality. The US Preventive Services Task Force (USPSTF) issues evidence-graded recommendations for the cancers where screening has been formally tested: breast (mammography), cervical (cytology and high-risk HPV testing), colorectal (multiple modalities including colonoscopy, FIT, and stool DNA), lung (low-dose CT in eligible heavy smokers), and skin (visual examination). USPSTF grades range from A (substantial net benefit, recommend) through D (no benefit or net harm, recommend against) and I (insufficient evidence) USPSTF 2024. Across the five sites in scope, claimed effects are: reductions in cancer-specific mortality (20–40% depending on site and modality), reductions in advanced-stage incidence, and — for cervical and colorectal — reductions in cancer incidence itself via removal of high-grade precursor lesions. The same screenings also produce documented harms: false positives, overdiagnosis (detection of cancers that would never have caused symptoms), procedural complications, and the psychological cost of follow-up. The entry's holistic scope: a longevity-tier preventive behavior; very low burden when followed on schedule; effort and cost driven by procedure-specific quirks (colonoscopy prep, mammogram callbacks); contested at the edges (mammogram start age, skin visual exam, modality choice).

Evidence by addressing question

Mechanism — why screening works (and when it doesn't)

Screening's premise is the natural history of cancer progression: most epithelial cancers pass through detectable precursor states (cervical intraepithelial neoplasia, colorectal adenomatous polyps), localized invasive states, regional spread, and distant metastasis. Survival drops sharply at each transition. For colorectal cancer, the 5-year survival is ~91% for localized disease versus ~15% for distant Siegel 2024; for breast, ~99% versus ~31%; for lung, ~65% versus ~9%. Screening intervenes before symptomatic presentation, when the lesion is small and curable, or — for cervical and colorectal — before it has become cancer at all.

Three sub-mechanisms map to the three classes of screening test:

Precursor removal (cervical, colorectal). Pap cytology and HPV testing detect dysplasia (CIN1–3); colonoscopy and sigmoidoscopy find and remove adenomatous polyps. Both prevent cancer rather than just detect it. Cervical cancer incidence in screened populations has dropped by 60–80% since organized screening began Ronco 2014; the Nishihara cohort showed colonoscopy reduces colorectal cancer incidence by ~40% and mortality by ~70% for distal cancers Nishihara 2013.
Stage-shifting (breast, lung). Mammography and low-dose CT (LDCT) do not prevent the cancer; they find it earlier. The trial-level benefit comes from detecting tumors at smaller size and lower stage, when surgical resection alone is curative. NLST showed a 20% relative reduction in lung-cancer-specific mortality (1.3 deaths per 1,000 screened) over 6.5 years with three annual LDCTs NLST 2011; the European NELSON trial replicated this with a 24% reduction in men and 33% in women using volume-CT criteria de Koning 2020.
Visual surface inspection (skin). A clinician (or the person themselves) inspects the skin for atypical pigmented lesions, applying ABCDE criteria (asymmetry, border, color, diameter, evolution) and the "ugly duckling" rule (a lesion that looks different from the patient's other moles). Mechanism is the simplest: melanoma is curable if excised before it invades past 1 mm vertical depth; depth predicts metastatic risk more than any other variable.

The screen-doesn't-help failure mode also has a mechanism: cancers that progress faster than the screening interval (interval cancers — especially aggressive triple-negative breast cancers and small-cell lung cancer) bypass the screening window entirely, and screening cannot help cancers whose biology dictates early metastasis regardless of tumor size at detection.

Evidence — what the trials show, site by site

Breast. The RCT base is eight trials run between the 1960s and 1990s — HIP, Edinburgh, Swedish Two-County, Malmö, Stockholm, Gothenburg, Canadian National Breast Screening Studies (CNBSS-1 and CNBSS-2), UK Age Trial. Meta-analyses converge on a 15–20% relative reduction in breast cancer mortality in women invited to screen versus controls Marmot 2013. The Swedish Two-County 29-year follow-up showed a 31% reduction in breast cancer mortality in invited women, with an absolute mortality benefit sustained across three decades Tabár 2011. Cochrane reanalysis is more conservative (15% RR reduction, possibly closer to zero in the highest-quality trials), and emphasizes overdiagnosis on the order of 19–30% of detected cancers Gøtzsche 2013. USPSTF's 2024 update lowered the start age from 50 to 40 on the basis of CISNET modeling that projected the largest absolute benefit per screening for Black women, who develop breast cancer earlier and die from it at higher rates USPSTF 2024. Recommended interval is biennial; ACR and the Society of Breast Imaging recommend annual Monticciolo 2023.

Cervical. The strongest evidence supports HPV testing (alone or as a co-test) over cytology alone for women ≥30. Pooled analysis of four European RCTs (Swedescreen, POBASCAM, ARTISTIC, NTCC) showed HPV-based screening reduces invasive cervical cancer incidence by 60–70% versus cytology over 6.5 years of follow-up Ronco 2014. USPSTF 2018 endorses three options for women 30–65: cytology every 3 years, hrHPV testing every 5 years, or co-testing every 5 years; for 21–29, cytology every 3 years USPSTF 2018. ACS 2020 has moved further: HPV-primary testing every 5 years for ages 25–65, with cytology and co-testing accepted alternatives Fontham 2020. The 2020 Swedish cohort of 1.7M women showed HPV vaccination before age 17 reduces invasive cervical cancer incidence by 88% — meaning the screened population is changing under the screening protocols' feet Lei 2020.

Colorectal. Four modalities have direct RCT evidence: guaiac fecal occult blood (gFOBT), flexible sigmoidoscopy, fecal immunochemical test (FIT), and (newly) colonoscopy. Minnesota gFOBT trial showed a 33% reduction in colorectal cancer mortality with annual screening over 13 years Mandel 1993. PLCO and UK Flexible Sigmoidoscopy trials each showed ~26–30% mortality reduction for distal colorectal cancers Schoen 2012. NordICC — the first colonoscopy RCT — reported a 31% intention-to-screen reduction in colorectal cancer risk over 10 years and an 18% reduction in death (the latter not significant in ITT analysis), with per-protocol effects substantially larger Bretthauer 2022. The Nishihara prospective cohort gave the headline figure: 68% reduction in colorectal cancer mortality among those undergoing colonoscopy Nishihara 2013. Multitarget stool DNA testing (Cologuard) detects 92% of cancers and 42% of advanced precancerous lesions versus 74%/24% for FIT — better sensitivity, worse specificity, with higher false positives requiring follow-up colonoscopy Imperiale 2014. USPSTF 2021 lowered the start age from 50 to 45 (Grade B) given rising incidence in young adults; 50–75 remains Grade A; 76–85 is individualized (Grade C) USPSTF 2021 Lin 2021.

Lung. Two large RCTs anchor LDCT screening. NLST (US, 53,454 participants, current/former smokers 55–74 with ≥30 pack-years, quit within 15y): 20% relative reduction in lung-cancer-specific mortality and 6.7% reduction in all-cause mortality versus chest X-ray NLST 2011. NELSON (Belgium/Netherlands, 15,792 participants, men 50–74 plus a smaller female cohort): 24% lung cancer mortality reduction in men, 33% in women at 10 years de Koning 2020. USPSTF 2021 expanded eligibility from the 2013 NLST-mirror criteria to ages 50–80 with ≥20 pack-years and quit within 15 years, roughly doubling the screen-eligible US population and improving racial equity USPSTF 2021. Lung-RADS standardization halved the false-positive rate without sacrificing sensitivity Pinsky 2015. ACS 2023 went further still — eligibility for any current/former smoker ≥50 with ≥20 pack-years, no requirement for quit-within-15-years Wolf 2024.

Skin. No RCT has shown a mortality benefit from visual skin exam screening in asymptomatic adults. The German SCREEN project (2003–2004 in Schleswig-Holstein, 360,000 adults screened) showed a 48% drop in melanoma mortality versus surrounding regions, but the effect attenuated and the trial was observational with significant confounding Katalinic 2012. USPSTF 2023 retained an I-statement (insufficient evidence) for skin cancer screening in asymptomatic adolescents and adults, citing absence of RCT mortality data and concern for overdiagnosis of indolent melanomas USPSTF 2023 Wernli 2016. Counseling about minimizing UV exposure for fair-skinned individuals 6 months to 24 years is Grade B; counseling 25+ is Grade C Henrikson 2018. Most US dermatologists still recommend annual or biennial full-body skin exams for high-risk patients (personal/family history of melanoma, many atypical nevi, immunosuppression, prior NMSC), even where USPSTF has not endorsed it for the general population.

Protocol — recommended ages, intervals, modalities

The USPSTF current schedule for average-risk adults:

Breast: Biennial mammography, women 40–74 (Grade B). Insufficient evidence for digital breast tomosynthesis as primary modality, or for supplemental ultrasound/MRI in women with dense breasts (I-statement) USPSTF 2024.
Cervical: Women 21–29, cytology every 3 years. Women 30–65, choice of cytology every 3 years, hrHPV every 5 years, or co-testing every 5 years. Stop at 65 if adequate prior screening with no high-grade lesions. After hysterectomy with removal of cervix for non-cancer indication: stop. (Grade A throughout 21–65; Grade D before 21 and after 65 with adequate prior screening) USPSTF 2018.
Colorectal: Ages 45–49 Grade B, 50–75 Grade A, 76–85 individualized Grade C. Acceptable modalities: colonoscopy every 10 years; FIT or high-sensitivity gFOBT annually; stool DNA-FIT every 1–3 years; CT colonography every 5 years; flexible sigmoidoscopy every 5 years (or every 10 years with annual FIT) USPSTF 2021.
Lung: Annual low-dose CT for adults 50–80 with ≥20 pack-year smoking history who currently smoke or quit within 15 years. Stop when a person has not smoked for ≥15 years, develops a health problem that limits life expectancy, or cannot tolerate curative lung surgery (Grade B) USPSTF 2021.
Skin: USPSTF: insufficient evidence (I-statement) for routine visual skin examination in asymptomatic adults. No graded schedule. High-risk individuals (prior melanoma, ≥5 atypical nevi, organ transplant recipients, very fair skin with high UV exposure history) are referred to dermatology for periodic exams as an off-USPSTF clinical practice USPSTF 2023.

Pack-year calculation for lung eligibility: packs per day × years smoked. 20 pack-years = one pack daily for 20 years, or two packs for 10. Lung-RADS 1–4 classification stratifies CT findings; only Lung-RADS 3–4 trigger short-interval follow-up or biopsy Pinsky 2015.

Contraindications — when not to screen

Screening is unhelpful or net-harmful when life expectancy is shorter than the lead time to symptomatic disease. Operational rules:

Limited life expectancy. Stopping rules apply at age 75 (colorectal individualized), 75 (breast, USPSTF), 65 (cervical), and 80 (lung) or when life expectancy is <10 years (cancers detected by screening generally need 5–10 years to produce mortality benefit) USPSTF 2021 USPSTF 2024.
Pregnancy. Mammography is generally deferred outside specific clinical indications. LDCT is not performed unless symptoms drive imaging. Pap cytology can be performed but biopsy for high-grade dysplasia is often deferred to postpartum.
Active treatment for unrelated serious illness. When the patient will not be a candidate for cancer treatment, screening detection has no actionable downstream path.
Procedure-specific contraindications. Colonoscopy: severe coagulopathy, recent MI, peritonitis. LDCT: pregnancy. Mammography: recent breast biopsy (timing matters), breast implants need specialized views.
Cervix-removed hysterectomy for benign disease + no high-grade history: screening can stop entirely (Grade D for continuation) USPSTF 2018.

Misconceptions

Several common beliefs about screening are wrong or substantially incomplete.

"Earlier detection always saves lives." False. Lead-time bias (longer survival from diagnosis without longer life), length-time bias (overrepresentation of indolent cancers in screening pools), and overdiagnosis (detection of cancers that would never have caused symptoms) all dissociate "earlier detection" from "longer life." Mammography overdiagnoses 19–30% of detected breast cancers Welch 2016. NLST overdiagnosed 18.5% of detected lung cancers Aberle 2013. Overdiagnosed cancers receive cancer treatment for a cancer that never needed treating.
"More frequent screening is better." Generally false. Annual mammography (vs biennial) roughly doubles cumulative false-positive risk over a decade without commensurate mortality reduction. Cervical screening every 1 year was abandoned in favor of every 3–5 because the marginal benefit was small and the colposcopy/LEEP harm was substantial.
"Skin checks at the dermatologist save lives." Insufficient evidence — USPSTF has held an I-statement since 2009 and reaffirmed in 2023 USPSTF 2023. This contradicts common practice but reflects the absence of RCT data.
"At-home stool tests are worse than colonoscopy." Misleading. Annual FIT has comparable mortality benefit to colonoscopy at 10 years in modeling studies; the harder problem is sustained adherence over decades. Stool DNA testing (Cologuard) detects more cancers than FIT per single round but generates more false positives that drive follow-up colonoscopy Imperiale 2014.
"If a screen is negative I'm cancer-free." Wrong. Interval cancers occur in all programs. Self-awareness of new symptoms (breast lump, rectal bleeding, changing skin lesion, hemoptysis) remains essential between rounds.
"USPSTF guidelines are the only guidelines." The American Cancer Society, ACOG, ACR, NCCN, and specialty societies differ — most notably mammography start age (ACR/SBI = 40 annual; ACS = 45 annual to 54, then biennial; USPSTF since 2024 = 40 biennial) and lung screening cessation criteria (ACS 2023 dropped the 15-year quit window) Wolf 2024 Monticciolo 2023.

Audience — sex- and risk-specific tracks

Sex-linked screenings: mammography (functionally female; male breast cancer is rare and not USPSTF-screened) and cervical (anatomical females and trans men with retained cervix). Cisgender men with a cervix-retaining anatomy: same screening guidelines apply. Trans women on long-term estrogen: no formal mammography guidance from USPSTF; specialty consensus suggests screening after 5+ years of feminizing hormones at age 50+.

Risk modifiers that change the schedule:

BRCA1/2 carriers and women with strong family history. MRI plus annual mammography starting age 25–30, well before USPSTF's average-risk start. Risk-reducing salpingo-oophorectomy may also be indicated.
Lynch syndrome (HNPCC). Colonoscopy every 1–2 years starting at 20–25, lifelong. Also screening for endometrial, gastric, urinary cancers.
Family history of colorectal cancer (first-degree relative). Start screening at age 40 or 10 years before the relative's diagnosis, whichever is earlier Smith ACS 2020.
Heavy smoking history not meeting USPSTF pack-year threshold. ACS 2023 dropped the 15-year quit-window requirement; some practitioners individualize LDCT below USPSTF threshold Wolf 2024.
Dense breast tissue (BI-RADS C or D). Most US states require notification; supplemental ultrasound or MRI is offered, though USPSTF has not graded it as net-beneficial yet USPSTF 2024.
Personal melanoma history or many atypical nevi. Dermatology referral every 3–12 months for full-body exams (no USPSTF endorsement, but standard of care).
Solid organ transplant or HIV. Risk-elevated for multiple cancers; screening intensified and started earlier by specialty consensus.

Alternatives — modality choices within each site

Within colorectal, all USPSTF-endorsed modalities are alternatives, not a hierarchy. The right test is the one the patient will actually complete on schedule. FIT annually has ~80% sensitivity for colorectal cancer per round and detects most cancers within 2 rounds; Cologuard's single-round sensitivity is higher (~92%) at the cost of more false positives Imperiale 2014. Colonoscopy is one-and-done for 10 years but requires bowel prep, sedation, and time off work. Modeling from the Australian National Bowel Cancer Screening Program (biennial FIT) showed ~70 lives saved per 10,000 invited over 40 years — comparable in magnitude to colonoscopy Lew 2019.

Within breast, digital breast tomosynthesis (3D mammography) has higher cancer detection and lower recall rates than 2D in dense breasts; ultrasound and MRI are supplemental options for women with dense tissue or elevated risk. USPSTF 2024 deferred a recommendation on tomosynthesis as primary modality pending more data USPSTF 2024.

Within cervical, the three USPSTF options for women 30–65 have similar net benefit; HPV-primary every 5 years is moving toward the consensus modality given the cleaner test characteristics and longer interval Ronco 2014 Fontham 2020.

Failure modes

Where screening goes wrong in real life:

Adherence collapse. Single-round screening of any modality does little; the mortality benefit requires sustained on-schedule participation over years. Most US adults are not up-to-date — only ~70% for breast, ~75% for cervical, ~70% for colorectal, ~6% of eligible adults for lung Smith ACS 2020.
Wrong start age relative to family history. A first-degree relative diagnosed at 45 shifts the index person's colorectal start from 45 to 35. Most patients don't know this; many clinicians don't ask the family-history question rigorously.
Lung eligibility unrecognized. Most current/former smokers eligible for LDCT under USPSTF 2021 are not screened — ~6% uptake nationally despite an estimated 14M eligible Americans Wolf 2024. The pack-year calculation is unfamiliar to both patients and many PCPs.
False-positive cascade. A positive screen produces a chain of follow-up tests; ~10% of mammograms recall for additional imaging; ~3% of LDCTs need biopsy; ~2% of colonoscopies have a complication (bleeding, perforation rate ~0.05%) USPSTF 2021.
Overdiagnosis and overtreatment. ~19% of mammography-detected breast cancers and ~18% of NLST-detected lung cancers are overdiagnoses Welch 2016 Aberle 2013. Patients receive curative surgery, radiation, or chemotherapy for cancers that would have caused no harm.
Inappropriate continuation past stopping age. Many women continue mammography into their 80s despite USPSTF's stop-at-75 and limited evidence of benefit when life expectancy is <10 years.

Practicalities

Under the Affordable Care Act, USPSTF Grade A and B preventive services must be covered by insurance without cost-sharing — including all the screenings in scope here at recommended intervals. Out-of-pocket cost is zero for the screening itself for most insured Americans; downstream diagnostic workup (a biopsy after a positive screen) may incur cost-sharing. Uninsured adults can use the CDC's National Breast and Cervical Cancer Early Detection Program (free for income-eligible) and state-level colorectal screening programs.

Time commitments per screening round, in normal-life units: mammogram 20–30 minutes plus travel; Pap smear 5–10 minutes during a routine visit; FIT 5 minutes at home plus mailing; colonoscopy 90 minutes plus a day of prep and a half-day of recovery; LDCT 10 minutes plus drive; visual skin exam 10 minutes during a clinic visit.

Stakes — what happens to a typical reader who doesn't screen

Probabilistic, not deterministic. For a 50-year-old US adult, lifetime cancer-death risk from the five screen-able cancers absent any screening is roughly: breast 2.5% (female), cervical 0.2% (female), colorectal 1.8%, lung 6.5% (heavy smoker) / 0.5% (never-smoker), melanoma 0.3% Siegel 2024. Screening reduces each by approximately the mortality reductions noted above. The felt-experience version: the next decade of a typical 55-year-old who doesn't get colonoscopied includes a meaningful (~1 in 50) chance of presenting with symptomatic colorectal cancer — bleeding, weight loss, fatigue — at a stage with 70%+ chance of curative resection if Stage I/II, dropping to ~15% 5-year survival at Stage IV. Cervical cancer's symptomatic presentation (postcoital bleeding, pelvic pain) typically reflects late-stage disease in a younger woman; with adequate screening this near-zero baseline becomes near-impossible.

Payoff — what changes after a clean screen on schedule

Direct effect: low. A negative screen produces brief reassurance and goes back into the background. The aggregate payoff over decades is the mortality reduction described in §evidence — for a 50-year-old completing the recommended schedule, an absolute lifetime risk reduction of roughly 0.5–1% for cancer death across all screened sites, which dwarfs nearly all other primary-prevention interventions in life-years saved per hour spent. The felt experience is mostly the absence of an alternate timeline: the polyp that would have become Stage III colon cancer at 62 was removed at colonoscopy at 55; the small DCIS found on mammogram at 53 was treated and gone by 54 with no recurrence at 65.

Out-of-scope

Prostate cancer screening (USPSTF Grade C for 55–69, individualized shared decision-making; Grade D for 70+) is not covered in this entry per the brief. Ovarian (Grade D — do not screen asymptomatic women), pancreatic (Grade D), oral (I-statement), and testicular (Grade D) are similarly excluded. Genetic risk assessment (BRCA1/2, Lynch syndrome) and chemoprevention (tamoxifen, aspirin) are adjacent but separate substances Johansson 2020.

Credibility range

Optimist case

USPSTF Grade A and B screenings represent the best-evidence preventive interventions in modern medicine. Multiple large RCTs, decades of organized-screening programs in Europe and Australia showing population-level mortality reductions, and convergent specialty-society guidelines (ACS, ACOG, ACR, NCCN) all endorse the core schedule. Cervical cancer mortality in the US dropped from ~14 per 100,000 in the 1950s to ~2.2 per 100,000 today, almost entirely attributable to Pap screening Siegel 2024. Colorectal cancer mortality has fallen ~50% over four decades, with about half of that decline attributable to screening (the other half to treatment advances and risk-factor changes) Lin 2021. Lung LDCT in heavy smokers prevents 20% of lung cancer deaths in eligible populations NLST 2011. The all-cause-mortality endpoint, which is more demanding than cancer-specific mortality, was significant in NLST. For an asymptomatic adult who follows the schedule, the expected absolute risk reduction is small per round but compounds over decades; in life-years saved per dollar and per hour of effort, organized screening sits near the top of preventive medicine's intervention list.

Skeptic case

The mortality benefit of mammography is smaller than commonly stated — Cochrane's reanalysis of the highest-quality trials yields a relative risk reduction closer to 10% than to 20%, and possibly null in the most rigorous trials Gøtzsche 2013. Overdiagnosis is substantial across modalities: ~19–30% of mammography-detected breast cancers, ~18% of NLST-detected lung cancers, an unknown but real fraction of small colorectal cancers and indolent melanomas Welch 2016 Aberle 2013. Overdiagnosed patients receive cancer treatment — surgery, radiation, chemotherapy — for cancers that would not have caused harm. False positives cause psychological morbidity that persists for months. Population-level evidence is dominated by trial-era practices that have shifted (mortality from breast cancer was already falling before mammography became widespread, complicating attribution). Skin cancer screening has no RCT mortality evidence at all USPSTF 2023. The lifetime cost of screening — measured in screening visits, follow-up procedures, biopsies, and overtreatment — is non-trivial both financially and physically, and the absolute benefit is small enough that informed reasonable patients can decline some screenings without behaving irrationally.

Author's call

The USPSTF schedule (Grade A and B) is the editorial floor. For breast, cervical, colorectal, and lung, the evidence is strong enough that an asymptomatic adult should follow the schedule by default; the modality choice within a site (colonoscopy vs FIT vs Cologuard; mammography start at 40 vs 45 vs 50) is where individualization happens. For skin, the article should report the USPSTF I-statement honestly — visual exam screening is widely practiced and intuitive, but the mortality benefit has not been demonstrated in RCTs and overdiagnosis is real. Overdiagnosis and false positives are addressed in the article body, not buried — readers deserve the full picture. The entry lands at high evidence (5/5) and moderate controversy (3/5), reflecting the genuine and substantial debates at the edges (start age, modality, dense breasts, skin screening) without obscuring the core consensus.

Stakeholder and incentive map

USPSTF. Federally-chartered independent panel; gold standard for US primary care. Conservative by design — requires direct evidence of benefit. Recommendations drive ACA insurance coverage mandates for Grade A/B.
Specialty societies. ACS, ACOG, ACR, NCCN, AAD, ACG. Often issue more aggressive guidelines (lower start ages, shorter intervals) than USPSTF. Membership includes practitioners who perform the screening procedures — a real conflict of interest, acknowledged in their disclosures.
Test manufacturers and providers. Cologuard (Exact Sciences), digital pathology, breast tomosynthesis vendors, LDCT-equipped imaging centers, dermatology private equity rollups. Commercial incentive favors more screening, more frequent screening, lower entry ages, novel modalities.
Health insurers and CMS. Must cover Grade A/B services without cost-sharing under ACA. Indirect incentive toward screenings with demonstrated cost-effectiveness and against modalities with high false-positive cascade costs.
Cochrane Collaboration and academic skeptics. Push back on overdiagnosis and overscreening (Gøtzsche, Welch). Their critiques shape USPSTF's evidence reviews even when not adopted as the final recommendation.
Patient advocacy organizations. Susan G. Komen, Colorectal Cancer Alliance, American Cancer Society fundraising arms. Strongly pro-screening; "early detection saves lives" messaging is core to their fundraising and survivor-narrative identity. Tend to underemphasize overdiagnosis.

Population variability

Race and ethnicity. Black women develop breast cancer ~5 years earlier on average and die from it at ~40% higher rates than white women, driving USPSTF's 2024 start-age reduction USPSTF 2024. Black men have higher colorectal cancer incidence and mortality; some specialty societies have endorsed colorectal screening start at 45 for Black adults since 2018. Hispanic women have higher cervical cancer incidence in the US, partly reflecting screening access. Indigenous populations have higher incidence of several screen-able cancers and chronically lower screening uptake.
Genetic risk. BRCA1/2, Lynch syndrome, Li-Fraumeni, ataxia-telangiectasia, PALB2 mutations all shift the schedule dramatically — earlier start, shorter intervals, additional modalities (MRI for breast, more frequent colonoscopy, sometimes risk-reducing surgery).
Smoking status. Determines LDCT eligibility entirely. Never-smokers are not eligible; the absolute lung cancer risk in never-smokers is low enough that screening would harm more than help.
Skin type. Fitzpatrick I–II (very fair) has the highest melanoma and NMSC risk; VI (very dark) has lower incidence but worse stage at diagnosis from underrecognition. Skin cancer screening guidance varies accordingly in clinical practice.
Geographic and access variation. Rural areas have lower screening uptake across all five sites; the gap is largest for LDCT (where availability is concentrated in academic medical centers) and colonoscopy.
Age at last screen / cumulative history. Stopping rules depend on adequate prior negative screens. A 65-year-old with no prior cervical screening should continue, not stop.

Knowledge gaps

No RCT of skin cancer screening has reported a mortality benefit. The German SCREEN project is the closest comparator but observational and confounded. The MELACHECK and DERMOSCREEN trials may eventually close this gap.
Multi-cancer early-detection (MCED) blood tests (Galleri, others) are being studied in large RCTs (NHS-Galleri); efficacy and overdiagnosis profile unknown. None has USPSTF endorsement as of 2024.
Optimal mammography modality (2D vs DBT, with or without supplemental ultrasound or MRI) in dense breasts is unsettled; TMIST trial is reporting in stages.
HPV-primary cervical screening interval optimization (5 vs 7 years) and the role of self-sampling at home are evolving; ACS 2020 and 2024 draft USPSTF moves toward HPV-primary.
Lung LDCT in light smokers (10–19 pack-years) and never-smokers with environmental exposure (radon, asbestos, secondhand smoke) is under study. NELSON enrolled some 10–14 pack-year participants but was underpowered for that subgroup.
Whether AI-augmented reading (mammography, LDCT, colonoscopy polyp detection) changes the benefit-harm balance is an open question; FDA has approved several systems but RCT-level data on patient outcomes is limited.
Discontinuation of screening in older adults — when exactly to stop, given heterogeneous life expectancy at 75 — is under-evidenced relative to start-age questions.

Scope and exclusions. The brief named breast, cervical, colorectal, lung, and skin. I covered all five. Prostate, ovarian, pancreatic, testicular, and oral cancer screening were not in scope; prostate is a real adjacent entry (USPSTF Grade C, shared decision-making) and I flagged it in out-of-scope. The other four are either Grade D (recommend against) or I-statement; they don't carry their own entry weight.

Skin handling. The cleanest editorial call was how prominently to flag the USPSTF I-statement on skin. I put it in the dek ("the fifth is widely practiced but unsettled"), the protocol callout, the evidence section, and the misconceptions list. Most readers will be surprised by this; many dermatologists do annual full-body exams. The article doesn't tell readers to skip dermatology — it tells them the trial data isn't there yet.

Mammography start age. USPSTF moved from 50 to 40 in April 2024. I used the new schedule throughout. ACR/SBI (40 annual) and ACS (45 annual, then 55 biennial) disagree at the edges; I named both in misconceptions rather than pretending consensus.

Action vs decide. The headline action is do — follow the schedule. The decision elements (modality choice, dense breasts, family history) are individualized within the do, not the headline behavior. decide would have been the alternative; I think do reads more honestly for a reader who needs a schedule.

Cadence. Chose yearly because the schedule is reviewed yearly even though specific tests recur on multi-year intervals. The closest alternative is course, which doesn't fit — there's no defined endpoint.

Score calls worth noting.

longevity 4 (not 5). Per-individual absolute risk reduction is ~0.5–1% lifetime cancer death. At a population level the impact is enormous, but the spec defines 5 as "dominant longevity effect" and reserves it for things like never-smoking — single interventions with hazard ratios across multiple disease endpoints. Screening collectively does that but not as a single intervention.
evidence 5. Easy call for breast/cervical/colorectal/lung. Skin is an I-statement; I let the article do the work of flagging it instead of dragging the aggregate evidence rating down to 4. The dossier and the body both name it.
controversy 3. Real disagreements at mammography start age, lung quit-window, skin exam, modality choice. Could argue 2 (the core schedule is genuinely settled) or 4 (the edges are loud). 3 feels honest.
mood 1 and health_short_term 1. Edge calls. I weighed the symmetric anxiety risk of the testing process against the agency/reassurance effect. Net small positive. Could be argued 0; the felt-experience rhythm is small but real, and the practicalities section gives both a paragraph of cover.

Future links. When these entries exist, add cross-links: prostate-cancer-screening (PSA shared decision), hpv-vaccine, brca-genetic-testing, sun-protection, colonoscopy-prep.

Audience scoping. Did not scope meta.audience because the schedule applies to everyone with age- and sex-specific tracks inside it. Scoping at the meta level (e.g., "female") would have hidden the entry from half of readers who still need the colon and lung pieces.

Contraindications. The closed-vocabulary tokens (pregnancy, blood-thinners, etc.) don't map cleanly to the schedule as a whole — they're per-test issues. I covered them in the contraindications section rather than in the meta token list.